myfortic magasýruþolin tafla 180 mg
novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg
myfortic magasýruþolin tafla 360 mg
novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg
tobradex augndropar, dreifa
novartis healthcare a/s - dexamethasonum fosfat; tobramycinum inn - augndropar, dreifa
kesimpta
novartis ireland ltd - ofatumumab - heila-og mænusigg, köstum tilkynnt - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
sandimmun innrennslisþykkni, lausn 50 mg/ml
novartis healthcare a/s - ciclosporinum inn - innrennslisþykkni, lausn - 50 mg/ml
diovan mixtúra, lausn 3 mg/ml
novartis healthcare a/s - valsartanum inn - mixtúra, lausn - 3 mg/ml
certican tafla 0,75 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg
certican tafla 0,5 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg
trileptal mixtúra, dreifa 60 mg/ml
novartis healthcare a/s - oxcarbazepinum inn - mixtúra, dreifa - 60 mg/ml
certican tafla 0,25 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg